Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Overweight or Obesity
NCT05567796Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
A Phase 3 trial of CagriSema in obesity, sponsored by Novo Nordisk. Started Nov 2022; status: active, not recruiting.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05567796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567796.